10x Genomics (TXG) Competitors $11.86 -0.20 (-1.64%) As of 10:22 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TXG vs. ADPT, PACB, TWST, VCYT, VNT, MIR, RAL, ST, CAMT, and EYPTShould you be buying 10x Genomics stock or one of its competitors? The main competitors of 10x Genomics include Adaptive Biotechnologies (ADPT), Pacific Biosciences of California (PACB), Twist Bioscience (TWST), Veracyte (VCYT), Vontier (VNT), Mirion Technologies (MIR), Ralliant (RAL), Sensata Technologies (ST), Camtek (CAMT), and Eyepoint Pharmaceuticals (EYPT). 10x Genomics vs. Its Competitors Adaptive Biotechnologies Pacific Biosciences of California Twist Bioscience Veracyte Vontier Mirion Technologies Ralliant Sensata Technologies Camtek Eyepoint Pharmaceuticals 10x Genomics (NASDAQ:TXG) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Do analysts prefer TXG or ADPT? 10x Genomics presently has a consensus price target of $13.65, indicating a potential upside of 15.11%. Adaptive Biotechnologies has a consensus price target of $12.38, indicating a potential downside of 4.46%. Given 10x Genomics' higher probable upside, equities research analysts clearly believe 10x Genomics is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 8 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.33Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Do institutionals and insiders believe in TXG or ADPT? 84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 9.4% of 10x Genomics shares are held by company insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, TXG or ADPT? 10x Genomics has a beta of 2, suggesting that its share price is 100% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Does the media refer more to TXG or ADPT? In the previous week, Adaptive Biotechnologies had 1 more articles in the media than 10x Genomics. MarketBeat recorded 5 mentions for Adaptive Biotechnologies and 4 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 1.53 beat Adaptive Biotechnologies' score of 1.03 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Adaptive Biotechnologies 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TXG or ADPT more profitable? 10x Genomics has a net margin of -13.13% compared to Adaptive Biotechnologies' net margin of -59.07%. 10x Genomics' return on equity of -12.88% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-13.13% -12.88% -10.03% Adaptive Biotechnologies -59.07%-60.93%-23.03% Which has preferable earnings & valuation, TXG or ADPT? Adaptive Biotechnologies has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.42-$182.63M-$0.70-16.95Adaptive Biotechnologies$205.22M9.61-$159.49M-$0.82-15.80 Summary10x Genomics beats Adaptive Biotechnologies on 9 of the 16 factors compared between the two stocks. Get 10x Genomics News Delivered to You Automatically Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TXG vs. The Competition Export to ExcelMetric10x GenomicsMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.47B$2.08B$5.70B$10.23BDividend YieldN/AN/A5.68%4.61%P/E Ratio-16.8235.6576.0426.13Price / Sales2.4210.86516.68165.77Price / CashN/A59.5337.5661.52Price / Book2.0410.7012.676.32Net Income-$182.63M-$63.46M$3.29B$270.94M7 Day Performance-10.61%9.83%0.09%-0.10%1 Month Performance-15.69%5.65%4.14%6.37%1 Year Performance-44.18%35.37%65.69%28.45% 10x Genomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TXG10x Genomics3.8932 of 5 stars$11.86-1.6%$13.65+15.1%-47.5%$1.47B$610.78M-16.821,240Positive NewsGap DownADPTAdaptive Biotechnologies3.4038 of 5 stars$13.08+3.7%$12.38-5.4%+207.4%$1.99B$178.96M-15.95790Positive NewsPACBPacific Biosciences of California2.1247 of 5 stars$1.20+2.6%$1.90+58.3%-27.7%$360.44M$154.01M-0.52730TWSTTwist Bioscience3.8737 of 5 stars$25.72+1.6%$49.40+92.1%-41.8%$1.55B$312.97M-17.74990VCYTVeracyte3.867 of 5 stars$31.87+3.2%$40.90+28.3%-3.1%$2.51B$445.76M96.58790Positive NewsVNTVontier3.7793 of 5 stars$42.79-0.1%$47.50+11.0%+27.1%$6.28B$2.98B16.278,000Positive NewsMIRMirion Technologies2.789 of 5 stars$23.46+3.2%$23.00-1.9%+108.6%$5.49B$860.80M781.832,860Trending NewsRALRalliant2.6971 of 5 stars$41.33+0.0%$55.13+33.4%N/A$4.66BN/A0.007,000STSensata Technologies4.6947 of 5 stars$31.86+1.9%$34.64+8.7%-15.4%$4.64B$3.75B42.4719,000Positive NewsCAMTCamtek2.8723 of 5 stars$87.65+0.7%$96.10+9.6%+35.6%$4.00B$471.59M32.11400EYPTEyepoint Pharmaceuticals1.7825 of 5 stars$13.41+0.4%$26.86+100.3%+68.8%$924.31M$51.90M-5.00120Positive News Related Companies and Tools Related Companies Adaptive Biotechnologies Alternatives Pacific Biosciences of California Alternatives Twist Bioscience Alternatives Veracyte Alternatives Vontier Alternatives Mirion Technologies Alternatives Ralliant Alternatives Sensata Technologies Alternatives Camtek Alternatives Eyepoint Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TXG) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics Please log in to your account or sign up in order to add this asset to your watchlist. Share 10x Genomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TXG Stock Alerts